FIELD: medicine.
SUBSTANCE: invention refers to medicine, namely to therapy, and concerns correction of anxiety-depressive disorders in patients with systemic connective tissue diseases. For this purpose, in addition to the traditional therapy of systemic connective tissue diseases, paroxetine is orally administered in an initial dose of 10 mg a day, followed by increasing dose to 20–30 mg a day. Duration of course is 3 months.
EFFECT: such mode of drug administration provides higher clinical effectiveness in the main disease combined with reducing depressive symptoms, including by increasing adherence to treatment.
1 cl, 2 ex
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD FOR TREATING ANXIOUS-DEPRESSIVE DISORDERS AND AUTONOMIC DISBALANCE IN PATIENTS WITH ACUTE MYOCARDIAL INFARCTION | 2005 |
|
RU2288712C2 |
| MEDICINAL AGENT, A PHARMACEUTICAL COMPOSITION, AN ACTIVE INGREDIENT OF THE PHARMACEUTICAL COMPOSITION AND A METHOD OF TREATING ANXIETY AND DEPRESSION IN THE PATIENTS WITH ACUTE MYOCARDIAL INFARCTION | 2018 |
|
RU2702128C1 |
| ACTIVE INGREDIENT OF THE PHARMACEUTICAL COMPOSITION USED FOR TREATING ANXIETY AND DEPRESSION IN PATIENTS WITH ACUTE MYOCARDIAL INFARCTION | 2019 |
|
RU2708233C1 |
| METHOD OF COMPLEX TREATMENT OF THEURAPEITICALLY REFRACTORY SITUATIONAL DEPRESSIONS | 2006 |
|
RU2338543C2 |
| METHOD FOR TREATING THE PATIENTS POSSESSING DEPRESSIVE ANXIETY DISORDERS | 1999 |
|
RU2157211C1 |
| METHOD FOR TREATING ALOPECIAS WITH CONCOMITANT PSYCHOSOMATIC DISORDERS | 2020 |
|
RU2756002C1 |
| METHOD OF DIAGNOSING AFFECTIVE DISORDERS IN PATIENTS WITH IHD BY DATA OF ENCEPHALOGRAPHIC EXAMINATION | 2009 |
|
RU2419383C1 |
| METHOD FOR TREATMENT OF PATIENTS WITH LICHEN PLANUS | 2016 |
|
RU2629601C1 |
| METHOD OF TREATMENT OF DUODENUM ULCER DISEASE COMPLICATED BY COMORBID ANXIOUS DEPRESSION DISORDERS | 2007 |
|
RU2357729C2 |
| METHOD FOR COMPLEX CORRECTION OF COMORBID PATHOLOGY IN PERIMENOPAUSAL WOMEN | 2019 |
|
RU2703137C1 |
